

A safe and efficient route for preparation of *N*-Boc- β^3 -amino acid methyl esters from α -amino acids and application to the formal syntheses of sedum alkaloids

Content


General Experimental	page 2
Experimental Procedures	page 3
NMR Spectra of New Compounds and Selected Known Compounds	page 23

General Experimental

Commercially available reagents were used without further purification unless otherwise stated. All solvents were distilled prior to use: toluene, benzene, diethyl ether and tetrahydrofuran were distilled from Na/benzophenone; while dichloromethane, dimethylformamide, acetonitrile, triethylamine and diisopropylethylamine were distilled from CaH₂. Methanol was distilled under a N₂ atmosphere from Mg/I₂. All reactions were conducted in oven-dried (120 °C) or flame-dried glasswares under a N₂ atmosphere, and at ambient temperature (20 to 25 °C) unless otherwise stated. All non-aqueous reactions were performed by standard syringe in septa techniques. Evaporation and concentration under reduced pressure was performed at 50-500 mbar. ¹H NMR spectra were recorded in CDCl₃ (unless stated otherwise) on a Bruker Avance AV600 or 400 at 600 MHz (150 MHz) or 400 MHz (100 MHz), respectively. Chemical shifts are reported as δ values (ppm) referenced to either a tetramethylsilane (TMS) internal standard or the signals due to the solvent residual. Data for ¹H NMR are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (Hz), integration. Some peptide intermediates exist as rotational conformers, the chemical shift for the minor isomers were indicated using parentheses next to the peak for their major isomers. Mass spectra were measured on ABI Q-star Elite. Optical rotations were measured on a Perkin-Elmer 351 polarimeter at 589 nm with a 100 mm path length cell at 20 °C (reported as follows: concentration (*c* in g/100 mL), solvent). The reaction progresses were checked on pre-coated thin layer chromatography (TLC) plates. TLC was carried out using pre-coated sheets (Qingdao silica gel 60-F250, 0.2 mm) which, after development, were visualized under UV light at 254nm. Flash column chromatography was performed using the indicated solvents on E. Qingdao silica gel 60 (230-400 mesh ASTM). Yields refer to chromatographically purified compounds, unless otherwise stated.


Experimental procedures

General Procedure A (GPA):




To a solution of **α -amino acid** (1.0 *eq.*) in MeOH was dropwise added SOCl_2 (3.0 *eq.*) at 0 °C. After 30 min, the resultant mixture was heated to reflux and stirred for 2h. The solution was cooled to room temperature and volatiles of the reaction mixture were removed in vacuo to obtain the **α -amino acid methyl ester hydrochloride**, which was used for next step directly.

General Procedure B (GPB):



To a solution of the above-obtained **α -amino acid methyl ester hydrochloride** (1.0 *eq.*) in THF/H₂O (1:1) was added NaHCO_3 (3.0 *eq.*) and Boc_2O (1.0 *eq.*) at 0 °C. After being stirred at room temperature for 10 h, volatiles of the reaction mixture were removed in vacuo. The solution was then diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by brine, dried over sodium sulfate (anhydrous) and concentrated in *vacuo* to give the **N-Boc- α -amino acid methyl ester**, which was used for next step directly.


General Procedure C (GPC):



To a solution of the above-obtained **N-Boc- α -amino acid methyl ester** (1.0 *eq.*) in dry THF was added LiAlH_4 (1.5 *eq.*) at temperatures below -50 °C. After 30 min, the resultant mixture was allowed to warm to room temperature slowly and stirred for 2h. The reaction was then quenched with saturated aqueous Na_2SO_4 solution at temperatures below -50 °C. Volatiles of the reaction


mixture were removed in vacuo. The solution was then diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by brine, dried over sodium sulfate (anhydrous) and concentrated in *vacuo* to give the **N-Boc- α -amino alcohol**, which was used for next step directly.

General Procedure D (GPD):



To a solution of the above-obtained **N-Boc- α -amino acid methyl ester** (1.0 *eq.*) in dry THF was added LiBH_4 (2.0 *eq.* — 5.0 *eq.*) at 0 °C. After 30 min, the resultant mixture was allowed to warm to room temperature slowly and stirred for 12h. The reaction was then quenched with saturated aqueous Na_2SO_4 solution at 0 °C. Volatiles of the reaction mixture were removed in vacuo. The solution was then diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by brine, dried over sodium sulfate (anhydrous) and concentrated in *vacuo* to give the **N-Boc- α -amino alcohol**, which was used for next step directly.

General Procedure E (GPE):




To a solution of the above-obtained **N-Boc- α -amino alcohol** (1.0 *eq.*) in dry MeCN was added IBX (1.2 *eq.*) at room temperature. After 15 min, the resultant mixture was heated to reflux and stirred for 1h. The solution was cooled to room temperature and the solid was removed by filtration through a pad of celite and washed with MeCN. The total filtrate was concentrated in vacuo to afford the **N-Boc- α -amino aldehyde**, which was used immediately for next step directly.

To a solution of the above-obtained **N-Boc- α -amino aldehyde** in i-PrOH was added

phosphonium reagent **2**^[1] (1.2 *eq.*) and K₂CO₃ (1.2 *eq.*) at room temperature. The resultant mixture was stirred at room temperature for 12h. The solid was removed by filtration through a pad of celite and washed with EtOAc. The total filtrate was concentrated in *vacuo*, then purified by silica gel column chromatography (EA/PE, 1:10) to afford the methyl 2-methoxy-2-alkenoates **3a-3k**.


General Procedure F (GPF):



To a solution of the above-obtained **3a-3k** (1.0 *eq.*) in dry DCM was added DIBAL-H (2.0 *eq.*) at -78 °C. The resultant mixture was stirred at -78 °C for 1h. The reaction was then quenched with saturated aqueous Na₂SO₄ solution at -78 °C. Volatiles of the reaction mixture were removed in *vacuo*. The solution was then diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by brine, dried over sodium sulfate (anhydrous) and concentrated in *vacuo* to give **4a-4k**, which was used immediately for next step directly.

To a solution of the above-obtained **4a-4k** in acetone was added TsOH (1.0 *eq.*) at 0 °C. The resultant mixture was stirred at 0 °C for 1h. The reaction was then quenched with Et₃N (2.0 *eq.*), then concentrated in *vacuo*, then purified by silica gel column chromatography (EA/PE, 1:2) to afford **5a-5k**.

General Procedure G (GPG):




To a solution of the above-obtained **5a-5k** (1.0 *eq.*) in THF/MeOH/H₂O (1:1:1) was added NaIO₄ (4.0 *eq.*) at room temperature. The resultant mixture was stirred at room temperature for 6h. The reaction was then quenched with saturated aqueous Na₂SO₃ solution. Volatiles of the reaction mixture were removed in *vacuo*. The solution was then diluted with water and adjusted to pH = 4

by addition of solid KHSO_4 . The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by brine, dried over sodium sulfate (anhydrous) and concentrated in *vacuo* to give the acid **6a-6k**, which was used immediately for next step directly.

To a solution of the above-obtained acid **6a-6k** in dry acetone was added K_2CO_3 (3.0 *eq.*) and MeI (1.5 *eq.*). After 15 min, the resultant mixture was heated to reflux and stirred for 10h. The solution was cooled to room temperature and the solid was removed by filtration through a pad of celite and washed with EtOAc. The total filtrate was concentrated in *vacuo*, then purified by silica gel column chromatography (EA/PE, 1:4) to afford **7a-7k**.

Methyl (S)-3-((tert-butoxycarbonyl)amino)-4-phenylbutanoate (**7a**)



Compound **3a** :

$[\alpha]_{\text{D}}^{25} +27.1$ (c 0.51, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.32 – 7.20 (m, 5H), 6.11 (d, $J = 8.6$ Hz, 1H), 4.80 (d, $J = 14.6$ Hz, 2H), 3.79 (s, 3H), 3.56 (s, 3H), 2.97 – 2.82 (m, 2H), 1.42 (s, 9H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 199.38, 163.81, 154.92, 146.00, 137.02, 129.53, 129.31, 128.41, 126.80, 126.65, 79.51, 59.88, 52.04, 48.30, 41.04, 28.33; HR-ESIMS m/z : calculated for $\text{C}_{18}\text{H}_{25}\text{NO}_5\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 358.1625, found 358.1630.

Compound **5a** :


$[\alpha]_{\text{D}}^{25} -20.0$ (c 0.59, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.27 (ddd, $J = 58.0, 32.0, 6.4$ Hz, 5H), 4.96 (d, $J = 6.4$ Hz, 1H), 4.27 – 4.12 (m, 3H), 3.14 (s, 1H), 2.98 (dd, $J = 12.0, 5.7$ Hz, 1H), 2.87 – 2.81 (m, 1H), 2.61 (d, $J = 4.9$ Hz, 2H), 1.42 (s, 9H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 208.71, 155.20, 137.48, 129.18, 128.64, 126.77, 79.68, 68.59, 48.63, 41.63, 40.34, 28.27; HR-ESIMS m/z : calculated for $\text{C}_{16}\text{H}_{23}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 316.1519, found 316.1525.

Compound **7a** :

$[\alpha]_{\text{D}}^{25} -17.4$ (c 0.46, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.33 – 7.19 (m, 5H), 5.07 (d, $J = 6.6$

Hz, 1H), 4.18 (s, 1H), 3.71 (s, 3H), 2.96 (dd, $J = 12.8, 5.7$ Hz, 1H), 2.83 (dd, $J = 13.4, 7.8$ Hz, 1H), 2.50 (ddd, $J = 42.2, 15.9, 5.6$ Hz, 2H), 1.43 (s, 9H); ^{13}C NMR (151 MHz, CDCl_3) δ 172.12, 155.11, 137.68, 129.35, 128.49, 126.57, 79.35, 77.21, 77.00, 76.79, 51.67, 48.75, 40.34, 37.50, 28.32; HR-ESIMS m/z : calculated for $\text{C}_{16}\text{H}_{23}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 316.1519, found 316.1524.

Methyl (S)-3-((tert-butoxycarbonyl)amino)hexanoate (7b)



Compound **3b** :

$[\alpha]_{\text{D}}^{25} -1.3$ (c 0.98, EtOAc); ^1H NMR (600 MHz, CDCl_3) δ 6.04 (d, $J = 8.8$ Hz, 1H), 4.66 (s, 1H), 4.53 (s, 1H), 3.77 (s, 3H), 3.72 (s, 3H), 1.59 – 1.47 (m, 2H), 1.42 (s, 9H), 1.37 – 1.31 (m, 2H), 0.91 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 164.04, 154.84, 145.96, 128.33, 79.31, 60.16, 52.00, 46.88, 37.36, 28.38, 18.90, 13.77; HR-ESIMS m/z : calculated for $\text{C}_{14}\text{H}_{25}\text{NO}_5\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 310.1625, found 310.1629.


Compound **5b** :

$[\alpha]_{\text{D}}^{25} -20.2$ (c 0.41, EtOAc); ^1H NMR (600 MHz, CDCl_3) δ 4.74 (d, $J = 6.7$ Hz, 1H), 4.23 (q, $J = 19.0$ Hz, 2H), 4.01 – 3.88 (m, 1H), 3.13 (s, 1H), 2.62 (s, 2H), 1.72 (s, 1H), 1.55 – 1.46 (m, 2H), 1.41 (d, $J = 11.7$ Hz, 9H), 1.38 – 1.27 (m, 2H), 0.91 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 208.68, 155.43, 79.56, 68.70, 47.46, 43.60, 36.94, 28.31, 19.36, 13.71; HR-ESIMS m/z : calculated for $\text{C}_{12}\text{H}_{23}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 268.1519, found 268.1522.

Compound **7b** :

$[\alpha]_{\text{D}}^{25} -15.8$ (c 0.53, EtOAc); ^1H NMR (600 MHz, CDCl_3) δ 4.90 (d, $J = 7.7$ Hz, 1H), 3.90 (d, $J = 4.9$ Hz, 1H), 3.67 (s, 3H), 2.50 (qd, $J = 15.4, 5.3$ Hz, 2H), 1.47 (dd, $J = 12.6, 6.1$ Hz, 2H), 1.42 (s, 9H), 1.38 – 1.30 (m, 2H), 0.90 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 172.18, 155.36, 79.14, 51.57, 47.34, 39.16, 36.74, 28.35, 19.33, 13.77; HR-ESIMS m/z : calculated for $\text{C}_{12}\text{H}_{23}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 268.1519, found 268.1524.

Methyl (3R,4S)-3-((tert-butoxycarbonyl)amino)-4-methylhexanoate (7c)



Compound **3c** :

$[\alpha]_D^{25}$ -2.1 (c 0.66, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 6.04 (d, $J = 9.1$ Hz, 1H), 4.75 (s, 1H), 4.50 (d, $J = 6.1$ Hz, 1H), 3.78 (s, 3H), 3.72 (s, 3H), 1.57 (s, 1H), 1.50 - 1.46 (m, 1H), 1.43 (d, $J = 9.7$ Hz, 9H), 1.15 - 1.07 (m, 1H), 0.91 (t, $J = 7.4$ Hz, 3H), 0.87 (d, $J = 6.8$ Hz, 3H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 164.03, 155.11, 146.51, 126.07, 79.28, 60.15, 52.03, 51.06, 39.44, 28.39, 25.56, 14.93, 11.54; HR-ESIMS m/z : calculated for $\text{C}_{15}\text{H}_{27}\text{NO}_5\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 324.1781, found 324.1785.

Compound **5c** :


$[\alpha]_D^{25}$ -12.1 (c 0.57, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 4.78 (d, $J = 8.3$ Hz, 1H), 4.24 (dd, $J = 61.5, 18.9$ Hz, 2H), 3.89 - 3.81 (m, 1H), 2.63 - 2.49 (m, 2H), 1.57 (d, $J = 9.3$ Hz, 1H), 1.46 (s, 1H), 1.40 (s, 9H), 1.09 (dt, $J = 14.6, 7.7$ Hz, 1H), 0.89 (t, $J = 7.4$ Hz, 3H), 0.85 (d, $J = 6.8$ Hz, 3H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 209.01, 155.52, 79.52, 77.21, 77.00, 76.79, 68.47, 51.73, 40.87, 38.59, 38.44, 28.26, 25.34, 15.33, 11.39; HR-ESIMS m/z : calculated for $\text{C}_{13}\text{H}_{25}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 282.1676, found 282.1679.

Compound **7c** :

$[\alpha]_D^{25}$ -10.6 (c 0.98, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 4.88 (d, $J = 8.6$ Hz, 1H), 3.83 (dd, $J = 12.2, 5.4$ Hz, 1H), 3.67 (s, 3H), 2.47 (ddd, $J = 22.4, 15.2, 5.8$ Hz, 2H), 1.60 - 1.54 (m, 1H), 1.50 (dd, $J = 15.7, 9.3$ Hz, 1H), 1.46 - 1.40 (m, 9H), 1.15 - 1.07 (m, 1H), 0.90 (t, $J = 7.4$ Hz, 3H), 0.86 (d, $J = 6.8$ Hz, 3H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 172.48, 155.42, 79.14, 77.21, 77.00, 76.79, 51.88, 51.68, 38.28, 36.59, 28.36, 25.43, 15.27, 11.44; HR-ESIMS m/z : calculated for $\text{C}_{13}\text{H}_{25}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 282.1676, found 282.1681.

Methyl (S)-3-((tert-butoxycarbonyl)amino)-4-(4-((triisopropylsilyloxy)phenyl)butanoate (7d)

Ref. *JACS* 2007, 129, 12320-12327



Compound **3d** :

$[\alpha]_D^{25} +23.2$ (c 1.0, EtOAc); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.02 (d, $J = 8.3$ Hz, 2H), 6.80 (d, $J = 8.3$ Hz, 2H), 6.06 (d, $J = 8.3$ Hz, 1H), 4.71 (s, 2H), 3.76 (s, 3H), 3.55 (s, 3H), 2.80 (qd, $J = 13.6, 6.3$ Hz, 2H), 1.40 (s, 9H), 1.26 – 1.19 (m, 3H), 1.09 (m, 18H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 163.85, 154.95, 154.84, 145.93, 130.38, 130.15, 129.35, 127.18, 119.82, 107.74, 79.81, 59.95, 51.98, 48.45, 40.27, 28.35, 17.88, 12.63; HR-ESIMS m/z : calculated for $\text{C}_{27}\text{H}_{45}\text{NO}_6\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 530.2908, found 530.2915.

Compound **5d** :


$[\alpha]_D^{25} -8.0$ (c 0.40 EtOAc); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 6.98 (d, $J = 8.3$ Hz, 2H), 6.80 (d, $J = 8.4$ Hz, 2H), 4.85 (d, $J = 15.3$ Hz, 2H), 4.14 (t, $J = 12.2$ Hz, 2H), 3.10 (s, 1H), 2.86 (dd, $J = 13.3, 6.6$ Hz, 1H), 2.73 (dd, $J = 13.5, 7.8$ Hz, 1H), 2.56 (d, $J = 5.0$ Hz, 2H), 1.40 (s, 9H), 1.27 – 1.20 (m, 3H), 1.10 – 1.05 (m, 18H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 208.76, 155.25, 154.93, 130.05, 120.07, 103.90, 79.66, 68.56, 48.80, 41.71, 39.56, 28.30, 17.86, 12.61; HR-ESIMS m/z : calculated for $\text{C}_{25}\text{H}_{43}\text{NO}_5\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 488.2803, found 488.2808.

Compound **7d** :

$[\alpha]_D^{25} -13.8$ (c 0.81, EtOAc); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.01 (d, $J = 8.3$ Hz, 2H), 6.80 (d, $J = 8.4$ Hz, 2H), 4.97 (s, 1H), 4.09 (s, 1H), 3.68 (s, 3H), 2.84 (dd, $J = 13.5, 6.2$ Hz, 1H), 2.73 (dd, $J = 13.6, 7.7$ Hz, 1H), 2.45 (qd, $J = 15.8, 5.6$ Hz, 2H), 1.41 (s, 9H), 1.23 (dd, $J = 14.9, 7.1$ Hz, 3H), 1.09 (d, $J = 7.2$ Hz, 18H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 171.83, 155.13, 154.76, 130.20, 119.89, 79.29,

51.62, 48.89, 39.53, 37.55, 28.35, 17.89, 12.64; HR-ESIMS m/z : calculated for $C_{25}H_{43}NO_5SiNa^+$
 $[M+Na]^+$: 488.2803, found 488.2808.

Methyl (R)-3-((tert-butoxycarbonyl)amino)-4-((tert-butyldiphenylsilyl)oxy)butanoate (7e)



Compound **3e** :

$[\alpha]_D^{25} +1.4$ (c 0.50 EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ 7.64 (dd, $J = 6.2, 5.6$ Hz, 4H), 7.44 – 7.35 (m, 6H), 6.21 (d, $J = 8.4$ Hz, 1H), 5.05 (s, 1H), 4.69 (s, 1H), 3.78 (s, 3H), 3.63 (s, 3H), 1.45 (s, 9H), 1.07 (s, 9H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 163.68, 155.15, 146.20, 141.79, 135.57, 135.52, 129.80, 127.73, 127.70, 107.34, 94.18, 79.45, 65.84, 60.01, 51.97, 48.87, 28.36, 26.81, 26.53, 19.25; HR-ESIMS m/z : calculated for $C_{28}H_{39}NO_6SiNa^+$ $[M+Na]^+$: 536.2439, found 436.2445.

Compound **5e** :


$[\alpha]_D^{25} +14.6$ (c 0.26, EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ 7.69 – 7.50 (m, 4H), 7.44 – 7.37 (m, 6H), 4.97 (s, 1H), 4.19 (s, 2H), 4.11 (s, 1H), 3.71 (d, $J = 4.1$ Hz, 2H), 2.68 (dt, $J = 15.9, 8.1$ Hz, 2H), 1.42 (s, 9H), 1.06 (s, 9H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 208.30, 155.07, 135.50, 132.81, 129.96, 127.85, 79.80, 68.44, 65.04, 48.61, 40.01, 28.31, 26.88, 19.26; HR-ESIMS m/z : calculated for $C_{26}H_{37}NO_5SiNa^+$ $[M+Na]^+$: 494.2333, found 494.2339.

Compound **7e** :

$[\alpha]_D^{25} +15.7$ (c 0.97, EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ 7.62 (d, $J = 6.9$ Hz, 4H), 7.45 – 7.35 (m, 6H), 5.05 (s, 1H), 4.11 (s, 1H), 3.70 (s, 2H), 3.64 (s, 3H), 2.64 (d, $J = 4.8$ Hz, 2H), 1.43 (s, 9H),

1.06 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.90, 154.83, 135.53, 133.01, 129.80, 127.75, 79.29, 77.32, 77.00, 76.68, 64.93, 51.63, 48.85, 35.91, 28.35, 26.83, 19.27; HR-ESIMS m/z : calculated for $\text{C}_{26}\text{H}_{37}\text{NO}_5\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 494.2333, found 494.2338.

Methyl (S)-3-((tert-butoxycarbonyl)amino)-4-(1-tosyl-1H-indol-3-yl)butanoate (7f)



Compound **3f** :

$[\alpha]_{\text{D}}^{25}$ -9.2 (c 1.15, EtOAc); ^1H NMR (400 MHz, CDCl_3) δ 7.97 (d, $J = 8.2$ Hz, 1H), 7.75 (d, $J = 8.3$ Hz, 2H), 7.56 (d, $J = 7.7$ Hz, 1H), 7.43 (s, 1H), 7.27 (ddd, $J = 24.8, 16.1, 7.9$ Hz, 4H), 6.09 (d, $J = 8.4$ Hz, 1H), 4.87 (d, $J = 7.4$ Hz, 2H), 3.79 (s, 3H), 3.46 (s, 3H), 3.09 - 2.88 (m, 2H), 2.34 (s, 3H), 1.44 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.52, 154.89, 144.76, 135.13, 135.06, 130.88, 129.77, 126.73, 126.29, 124.70, 124.22, 123.12, 119.69, 118.12, 113.56, 79.66, 59.69, 52.00, 46.94, 30.49, 28.28, 21.46; HR-ESIMS m/z : calculated for $\text{C}_{27}\text{H}_{32}\text{N}_2\text{O}_7\text{SNa}^+$ $[\text{M}+\text{Na}]^+$: 551.1822, found 551.1829.

Compound **5f** :


$[\alpha]_{\text{D}}^{25}$ -15.2 (c 0.87, EtOAc); ^1H NMR (400 MHz, CDCl_3) δ 8.01 (d, $J = 8.2$ Hz, 1H), 7.77 (d, $J = 8.3$ Hz, 2H), 7.56 (d, $J = 7.8$ Hz, 1H), 7.42 - 7.23 (m, 5H), 4.99 (d, $J = 6.4$ Hz, 1H), 4.22 - 4.11 (m, 2H), 3.09 - 2.92 (m, 2H), 2.64 (d, $J = 2.5$ Hz, 2H), 2.36 (s, 3H), 1.44 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 208.55, 155.17, 144.92, 135.21, 135.15, 130.64, 129.83, 126.74, 124.93, 124.17, 123.32, 119.51, 118.61, 113.74, 79.86, 68.55, 47.18, 41.74, 29.69, 28.25, 21.50; HR-ESIMS m/z :

calculated for $C_{25}H_{30}N_2O_6SNa^+$ $[M+Na]^+$: 509.1717, found 509.1721.

Compound **7f** :

$[\alpha]_D^{25}$ -18.9 (c 0.97, EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ 7.97 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 8.3 Hz, 2H), 7.56 (d, J = 7.7 Hz, 1H), 7.43 (s, 1H), 7.27 (ddd, J = 24.8, 16.1, 7.9 Hz, 4H), 6.09 (d, J = 8.4 Hz, 1H), 4.87 (d, J = 7.4 Hz, 2H), 3.79 (s, 3H), 3.46 (s, 3H), 3.09 – 2.88 (m, 2H), 2.34 (s, 3H), 1.44 (s, 9H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 171.95, 155.11, 144.78, 135.23, 135.18, 130.83, 129.79, 126.74, 124.78, 124.27, 123.24, 119.68, 118.82, 113.69, 79.53, 51.69, 47.25, 37.47, 29.64, 28.29, 21.48; HR-ESIMS m/z : calculated for $C_{25}H_{30}N_2O_6SNa^+$ $[M+Na]^+$: 509.1717, found 509.1721.

Methyl (3R,4R)-3-((tert-butoxycarbonyl)amino)-4-((tert-butyldimethylsilyl)oxy)pentanoate (7g)



Compound **3g** :

$[\alpha]_D^{25}$ -7.40 (c 0.73, EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ 6.15 (d, J = 8.9 Hz, 1H), 4.98 (d, J = 7.0 Hz, 1H), 4.48 (s, 1H), 3.89 (d, J = 4.7 Hz, 1H), 3.77 (s, 3H), 3.73 (s, 3H), 1.44 (s, 9H), 1.17 (d, J = 6.2 Hz, 3H), 0.88 (s, 9H), 0.02 (d, J = 9.2 Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 163.91, 155.56, 145.48, 127.92, 79.37, 70.61, 60.27, 52.39, 51.96, 28.39, 25.76, 20.78, 17.97, -4.50, -5.04; HR-ESIMS m/z : calculated for $C_{19}H_{37}NO_6SiNa^+$ $[M+Na]^+$: 426.2282, found 426.2286.


Compound **5g** :

$[\alpha]_D^{25} +0.42$ (c 0.24, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 4.82 (d, $J = 8.8$ Hz, 1H), 4.25 (dd, $J = 11.3, 4.3$ Hz, 2H), 3.95 (dd, $J = 13.9, 6.8$ Hz, 2H), 3.13 (s, 1H), 2.61 (qd, $J = 15.4, 6.7$ Hz, 2H), 1.43 (s, 9H), 1.15 (d, $J = 6.1$ Hz, 3H), 0.89 (s, 9H), 0.05 (d, $J = 18.9$ Hz, 6H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 208.15, 155.78, 79.73, 69.19, 68.42, 52.46, 41.86, 28.32, 25.82, 20.59, 17.98, -4.24, -4.93; HR-ESIMS m/z : calculated for $\text{C}_{17}\text{H}_{35}\text{NO}_5\text{SiNa}^+ [\text{M}+\text{Na}]^+$: 384.2177, found 384.2180.

Compound **7g** :

$[\alpha]_D^{25} +3.1$ (c 0.29, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 4.81 (d, $J = 9.1$ Hz, 1H), 3.92 (dd, $J = 14.6, 6.7$ Hz, 2H), 3.66 (s, 3H), 2.50 (d, $J = 7.0$ Hz, 2H), 1.44 (s, 9H), 1.14 (d, $J = 6.1$ Hz, 3H), 0.89 (s, 9H), 0.05 (d, $J = 10.6$ Hz, 6H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 171.93, 155.64, 79.34, 68.89, 52.83, 51.65, 37.51, 28.35, 25.82, 20.67, 17.97, -4.31, -5.07; HR-ESIMS m/z : calculated for $\text{C}_{17}\text{H}_{35}\text{NO}_5\text{SiNa}^+ [\text{M}+\text{Na}]^+$: 384.2177, found 384.2180.

Methyl (R)-3-((tert-butoxycarbonyl)amino)-3-(4-((triisopropylsilyloxy)phenyl)propanoate (7h)



Compound **3h** :

$[\alpha]_D^{25} -18.1$ (c 0.47, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.15 (d, $J = 8.5$ Hz, 2H), 6.85 – 6.80

(m, 2H), 6.32 (d, $J = 8.5$ Hz, 1H), 5.65 (s, 1H), 5.04 (s, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 1.43 (s, 9H), 1.23 (dt, $J = 14.9, 7.5$ Hz, 3H), 1.08 (d, $J = 7.4$ Hz, 18H); ^{13}C NMR (151 MHz, CDCl_3) δ 163.95, 155.58, 154.86, 145.72, 132.87, 127.66, 127.42, 120.02, 79.69, 60.04, 52.05, 50.09, 28.35, 17.87, 12.61; HR-ESIMS m/z : calculated for $\text{C}_{26}\text{H}_{43}\text{NO}_6\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 516.2752, found 516.2754.

Compound **5h** :

$[\alpha]_{\text{D}}^{25} +16.3$ (c 0.46, EtOAc); ^1H NMR (600 MHz, CDCl_3) δ 7.15 (d, $J = 8.5$ Hz, 2H), 6.85 – 6.80 (m, 2H), 6.32 (d, $J = 8.5$ Hz, 1H), 5.65 (s, 1H), 5.04 (s, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 1.43 (s, 9H), 1.23 (dt, $J = 14.9, 7.5$ Hz, 3H), 1.08 (d, $J = 7.4$ Hz, 18H); ^{13}C NMR (151 MHz, CDCl_3) δ 207.91, 155.64, 155.04, 132.94, 127.25, 120.13, 79.92, 68.81, 50.78, 44.92, 28.27, 17.84, 12.58; HR-ESIMS m/z : calculated for $\text{C}_{24}\text{H}_{41}\text{NO}_5\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 474.2646, found 474.2649.


Compound **7h** :

$[\alpha]_{\text{D}}^{25} +20.3$ (c 0.62, EtOAc); ^1H NMR (600 MHz, CDCl_3) δ 7.15 (d, $J = 8.5$ Hz, 2H), 6.85 – 6.80 (m, 2H), 6.32 (d, $J = 8.5$ Hz, 1H), 5.65 (s, 1H), 5.04 (s, 1H), 3.77 (s, 3H), 3.67 (s, 3H), 1.43 (s, 9H), 1.23 (dt, $J = 14.9, 7.5$ Hz, 3H), 1.08 (d, $J = 7.4$ Hz, 18H); ^{13}C NMR (151 MHz, CDCl_3) δ 171.43, 155.36, 154.99, 133.10, 127.19, 119.91, 79.57, 51.65, 50.72, 40.91, 28.29, 17.84, 12.58; HR-ESIMS m/z : calculated for $\text{C}_{24}\text{H}_{41}\text{NO}_5\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 474.2646, found 474.2649.

Methyl (S)-3-((tert-butoxycarbonyl)amino)-5-((tert-butyldiphenylsilyl)oxy)pentanoate (**7i**)

Ref. [Synthesis 1995, 810-814](#)

Similar Ref. [Tetrahedron 2005, 61, 10277-10284](#)



Compound **3i** :

$[\alpha]_{\text{D}}^{25} +3.5$ (c 0.51, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.70 – 7.64 (m, 4H), 7.45 – 7.38 (m, 6H), 6.22 (d, $J = 7.9$ Hz, 1H), 5.72 (s, 1H), 4.74 (dd, $J = 7.7, 4.6$ Hz, 1H), 3.78 (s, 3H), 3.76 (s, 1H), 3.73 (s, 3H), 3.71 (s, 1H), 1.89 (s, 1H), 1.77 (s, 1H), 1.43 (s, 9H), 1.07 (s, 9H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 163.88, 155.22, 145.40, 135.54, 133.03, 129.86, 129.77, 129.12, 127.79, 127.74, 79.06, 61.49, 59.99, 51.95, 46.25, 36.05, 28.42, 26.77, 19.03; HR-ESIMS m/z : calculated for $\text{C}_{29}\text{H}_{41}\text{NO}_6\text{SiNa}^+ [\text{M}+\text{Na}]^+$: 550.2595, found 550.2598.

Compound **5i** :


$[\alpha]_{\text{D}}^{25} -6.4$ (c 0.33, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.69 – 7.58 (m, 4H), 7.42 (dt, $J = 28.1, 7.3$ Hz, 6H), 5.49 (d, $J = 6.1$ Hz, 1H), 4.20 (t, $J = 4.3$ Hz, 2H), 4.16 – 4.06 (m, 1H), 3.78 – 3.69 (m, 2H), 3.11 (t, $J = 4.2$ Hz, 1H), 2.79 (dd, $J = 15.6, 5.2$ Hz, 1H), 2.59 (dd, $J = 15.6, 6.3$ Hz, 1H), 1.85 (d, $J = 3.9$ Hz, 1H), 1.76 (d, $J = 5.0$ Hz, 1H), 1.41 (s, 9H), 1.06 (s, 9H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 208.43, 155.45, 135.53, 135.51, 133.01, 129.83, 127.78, 79.38, 68.62, 61.29, 46.42, 43.11, 35.76, 28.32, 26.81, 19.03; HR-ESIMS m/z : calculated for $\text{C}_{27}\text{H}_{39}\text{NO}_5\text{SiNa}^+ [\text{M}+\text{Na}]^+$: 508.2490, found 508.2493.

Compound **7i** :

$[\alpha]_{\text{D}}^{25} -4.8$ (c 0.60, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.70 – 7.62 (m, 4H), 7.41 (dt, $J = 26.8, 7.4$ Hz, 6H), 5.44 (d, $J = 7.3$ Hz, 1H), 4.16 – 4.06 (m, 1H), 3.80 – 3.75 (m, 1H), 3.70 (dt, $J = 10.6, 5.2$ Hz, 1H), 3.67 (d, $J = 16.7$ Hz, 3H), 2.71 (dd, $J = 15.4, 4.6$ Hz, 1H), 2.53 (dd, $J = 15.5, 6.7$ Hz, 1H), 1.86 (d, $J = 5.3$ Hz, 1H), 1.76 (dd, $J = 12.8, 5.3$ Hz, 1H), 1.42 (s, 9H), 1.05 (s, 9H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 172.06, 155.26, 135.54, 135.53, 133.24, 129.71, 127.71, 79.06, 61.30, 51.57, 46.30, 38.85, 35.80, 28.36, 26.79, 19.05; HR-ESIMS m/z : calculated for $\text{C}_{27}\text{H}_{39}\text{NO}_5\text{SiNa}^+ [\text{M}+\text{Na}]^+$: 508.2490, found 508.2493.

Methyl (S)-3-((tert-butoxycarbonyl)amino)-6-((tert-butylidiphenylsilyl)oxy)hexanoate (7j)

Ref. [Synthesis 2010, 293-303](#)



Compound **3j** :

$[\alpha]_D^{25}$ -0.91 (c 0.44, EtOAc); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.66 (d, $J = 6.4$ Hz, 4H), 7.42 – 7.38 (m, 6H), 6.08 (d, $J = 8.7$ Hz, 1H), 4.84 (s, 1H), 4.55 (s, 1H), 3.79 (s, 3H), 3.72 (s, 3H), 3.68 (d, $J = 6.3$ Hz, 2H), 1.68 – 1.57 (m, 4H), 1.44 (s, 9H), 1.06 (s, 9H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 163.93, 155.05, 145.87, 135.47, 133.74, 129.53, 127.57, 79.26, 63.33, 60.06, 51.94, 46.98, 31.42, 28.59, 28.35, 26.81, 19.13; HR-ESIMS m/z : calculated for $\text{C}_{30}\text{H}_{43}\text{NO}_6\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 564.2752, found 564.2759.

Compound **5j** :


$[\alpha]_D^{25}$ -10.3 (c 0.38, EtOAc); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.67 – 7.63 (m, 4H), 7.40 (ddd, $J = 16.6, 9.6, 4.7$ Hz, 6H), 4.85 (d, $J = 7.6$ Hz, 1H), 4.22 (q, $J = 19.0$ Hz, 2H), 3.91 (s, 1H), 3.67 (s, 2H), 3.15 (s, 1H), 2.61 (d, $J = 5.4$ Hz, 2H), 1.65-1.53 (m, 4H), 1.42 (s, 9H), 1.05 (s, 9H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 208.53, 155.43, 135.50, 133.73, 129.61, 127.63, 79.55, 68.67, 63.46, 63.25, 47.59, 43.62, 31.04, 29.03, 28.30, 26.84, 19.15; HR-ESIMS m/z : calculated for $\text{C}_{28}\text{H}_{41}\text{NO}_5\text{SiNa}^+$ $[\text{M}+\text{Na}]^+$: 522.2646, found 522.2651.

Compound **7j** :

$[\alpha]_D^{25}$ -6.8 (c 0.41, EtOAc); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.65 (dd, $J = 7.8, 1.5$ Hz, 4H), 7.44 – 7.35 (m, 6H), 4.95 (d, $J = 8.3$ Hz, 1H), 3.92 (d, $J = 17.4$ Hz, 1H), 3.67 (s, 3H), 3.67 – 3.58 (m, 2H), 2.51 (d, $J = 5.3$ Hz, 2H), 1.64 – 1.53 (m, 4H), 1.43 (s, 9H), 1.04 (s, 9H); $^{13}\text{C NMR}$ (101 MHz, CDCl_3)

δ 172.06, 155.38, 135.52, 133.84, 129.56, 127.61, 79.20, 63.41, 51.60, 47.54, 39.26, 30.89, 29.13, 28.36, 26.84, 19.18; HR-ESIMS m/z: calculated for $C_{28}H_{41}NO_5SiNa^+$ $[M+Na]^+$: 522.2646, found 522.2651.

Methyl (S,E)-6-(2,3-bis((benzyloxy)carbonyl)guanidino)-3-((tert-butoxycarbonyl)amino)hexanoate (8c)



To a solution of **7j** (1.0 *eq.*) in MeOH was added NH_4F (30 *eq.*) at room temperature. Then the resultant mixture was stirred and heated to reflux for 2h. The solution was concentrated in vacuo and the residue was diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by saturated aqueous solution of $NaHCO_3$, brine, dried over sodium sulfate (anhydrous) and concentrated in vacuo to give the corresponding primary alcohol **8a**, which was used immediately for next step directly.

To a solution of the above-obtained primary alcohol **8a** in toluene was added DPPA (2.0 *eq.*) and DBU (2.0 *eq.*). The reaction mixture was heated to reflux for 1h. After concentrated in vacuo, the residue was purified by silica gel column chromatography (EA/PE, 1:4) to afford the compound **8b** (80% over two steps) as an oil.

Compound **8b** :


$[\alpha]_D^{25}$ -3.2 (c 0.65, EtOAc); 1H NMR (600 MHz, $CDCl_3$) δ 4.98 (d, $J = 8.7$ Hz, 1H), 3.92 (s, 1H), 3.69 (s, 3H), 3.30 (t, $J = 6.6$ Hz, 2H), 2.54 (qd, $J = 15.8, 5.3$ Hz, 2H), 1.70 – 1.65 (m, 1H), 1.63 – 1.54 (m, 3H), 1.43 (s, 9H); ^{13}C NMR (151 MHz, $CDCl_3$) δ 171.97, 155.38, 79.47, 51.73, 51.02, 46.98, 39.16, 31.74, 28.34, 25.67; HR-ESIMS m/z: calculated for $C_{12}H_{22}N_4O_4Na^+$ $[M+Na]^+$: 309.1533, found 309.1536.

To a solution of the above-obtained compound **8b** (1.0 *eq.*) in THF/H₂O (20:1) was added bis-Cbz carboxamidine (1.1 *eq.*) and Ph₃P (3.0 *eq.*). The reaction mixture was heated to reflux for 2h. After concentrated in vacuo, the residue was purified by silica gel column chromatography (EA/PE, 1:2) to afford the compound **8c** (90%) as an oil.

Compound **8c** :

[α]_D²⁵ -2.1 (c 0.77, EtOAc); ¹H NMR (600 MHz, CDCl₃) δ 11.76 (s, 1H), 8.34 (s, 1H), 7.56 – 7.22 (m, 10H), 5.18 (t, *J* = 22.1 Hz, 4H), 5.05 (d, *J* = 8.6 Hz, 1H), 3.94 (s, 1H), 3.68 (s, 3H), 3.45 (dd, *J* = 12.5, 6.3 Hz, 2H), 2.53 (dd, *J* = 14.1, 8.3 Hz, 2H), 1.70 – 1.54 (m, 4H), 1.44 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 171.86, 163.61, 155.93, 155.27, 153.76, 136.69, 134.52, 128.69, 128.60, 128.36, 128.30, 127.99, 127.80, 79.27, 77.21, 77.00, 76.79, 68.06, 67.03, 51.60, 47.21, 40.60, 39.11, 31.59, 28.27, 25.82; HR-ESIMS *m/z*: calculated for C₂₉H₃₈N₄O₈Na⁺ [M+Na]⁺: 593.2582, found 593.2585.

Methyl (S)-3-((tert-butoxycarbonyl)amino)-7-((tert-butylidiphenylsilyl)oxy)heptanoate (7k)



Compound **3k** :

[α]_D²⁵ +2.5 (c 0.63, EtOAc); ¹H NMR (600 MHz, CDCl₃) δ 7.65 (d, *J* = 7.7 Hz, 4H), 7.42 – 7.36 (m, 6H), 6.04 (d, *J* = 8.7 Hz, 1H), 4.65 (s, 1H), 4.52 (s, 1H), 3.78 (s, 3H), 3.72 (s, 3H), 3.64 (t, *J* = 6.3 Hz, 2H), 1.63 – 1.45 (m, 6H), 1.43 (s, 9H), 1.04 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 163.98, 155.02, 145.98, 135.54, 133.97, 129.51, 128.18, 127.58, 79.33, 63.49, 60.14, 51.99, 47.08,

34.89, 32.15, 28.38, 26.83, 21.95, 19.17; HR-ESIMS m/z: calculated for C₃₁H₄₅NO₆SiNa⁺

[M+Na]⁺: 578.2908, found 578.2912.


Compound **5k** :

[α]_D²⁵ -1.3 (c 0.95, EtOAc); ¹H NMR (600 MHz, CDCl₃) δ 7.65 (dt, *J* = 8.0, 1.4 Hz, 4H), 7.47 – 7.34 (m, 6H), 4.72 (d, *J* = 8.1 Hz, 1H), 4.22 (dd, *J* = 44.0, 19.0 Hz, 2H), 3.90 (d, *J* = 5.8 Hz, 1H), 3.67 – 3.62 (m, 2H), 3.11 (s, 1H), 2.59 (d, *J* = 4.6 Hz, 2H), 1.55 (ddd, *J* = 8.6, 5.4, 2.5 Hz, 2H), 1.46 (dd, *J* = 13.7, 5.4 Hz, 4H), 1.43 (d, *J* = 13.9 Hz, 9H), 1.04 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 208.60, 155.40, 135.54, 133.92, 129.55, 127.60, 79.56, 68.67, 63.48, 47.65, 43.51, 34.45, 32.05, 28.31, 26.85, 22.49, 19.18; HR-ESIMS m/z: calculated for C₂₉H₄₃NO₅SiNa⁺ [M+Na]⁺: 536.2803, found 536.2806.

Compound **7k** :

[α]_D²⁵ -4.7 (c 0.57, EtOAc); ¹H NMR (600 MHz, CDCl₃) δ 7.65 (dt, *J* = 8.1, 1.4 Hz, 4H), 7.39 (dt, *J* = 14.3, 7.0 Hz, 6H), 4.88 (d, *J* = 8.8 Hz, 1H), 3.88 (s, 1H), 3.67 (s, 3H), 3.64 (t, *J* = 6.2 Hz, 2H), 2.49 (qd, *J* = 15.5, 5.2 Hz, 2H), 1.59 – 1.52 (m, 2H), 1.50 – 1.43 (m, 4H), 1.45 – 1.39 (m, 9H), 1.04 (s, 9H); ¹³C NMR (151 MHz, CDCl₃) δ 172.16, 155.33, 135.55, 133.99, 129.51, 127.59, 79.17, 63.58, 51.60, 47.56, 39.10, 34.30, 32.19, 28.36, 26.85, 22.47, 19.18; HR-ESIMS m/z: calculated for C₂₉H₄₃NO₅SiNa⁺ [M+Na]⁺: 536.2803, found 536.2806.

Tert-butyl (S)-2-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate (**9a**)



To a solution of **7j** (1.0 eq.) in MeOH was added NH₄F (30 eq.) at room temperature. Then the resultant mixture was stirred and heated to reflux for 2h. The solution was concentrated in vacuo and the residue was diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by saturated aqueous solution of NaHCO₃,


brine, dried over sodium sulfate (anhydrous) and concentrated in vacuo to give the corresponding primary alcohol **8a**, which was used immediately for next step directly.

To a solution of the above-obtained primary alcohol **8a** in dry DCM was added Et₃N (3.0 *eq.*) and MsCl (2.0 *eq.*) at 0 °C. After 15 min, the resultant mixture was allowed to warm to room temperature and stirred for 2h at N₂ atmosphere. The reaction was then quenched with saturated aqueous NaHCO₃ solution and extracted with DCM for 3 times. The combined organic layer was washed successively with saturated aqueous KHSO₄ solution, saturated aqueous solution of NaHCO₃, brine, and dried over anhydrous Na₂SO₄, filtered, concentrated in vacuo to give the compound **8d** as an oil, which was pure enough and could be used for next step directly.

To a solution of the above-obtained compound **8d** in dry THF was added t-BuOK (2.0 *eq.*) at 0 °C. After 20 min, the resultant mixture was allowed to warm to room temperature and stirred for 2h at N₂ atmosphere. The reaction was then quenched with saturated aqueous NH₄Cl solution. Volatiles of the reaction mixture were removed in vacuo. The solution was then diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by brine, dried over sodium sulfate (anhydrous) and concentrated in *vacuo*. The residue was purified by silica gel column chromatography (EA/PE, 1:4) to afford the compound **9a** (80% over 3 steps) as an oil.

[α]_D²⁵ -18.5 (c 0.13, EtOAc); ¹H NMR (600 MHz, CD₃CN) (*exists as rotamers*) δ 4.03 (dd, *J* = 10.5, 6.4 Hz, 1H), 3.61 (s, 3H), 3.27 (t, *J* = 7.3 Hz, 2H), 2.75 (s, 1H), 2.38 – 2.28 (m, 1H), 2.01 (s, 1H), 1.86 – 1.74 (m, 2H), 1.69 (s, 1H), 1.42 (s, 9H); ¹³C NMR (151 MHz, CD₃CN) (*exists as rotamers*) δ 172.85, 155.17, 154.94, 118.36, 79.84, 79.66, 55.11, 52.04, 47.36, 46.99, 39.72, 39.07, 31.90, 31.20, 28.64, 24.14, 23.36, 1.73, 1.60, 1.46, 1.32, 1.18, 1.04, 0.91; HR-ESIMS *m/z*: calculated for C₁₂H₂₁NO₄Na⁺ [M+Na]⁺: 266.1363, found 266.1365.

Methyl (S)-7-azido-3-((tert-butoxycarbonyl)amino)heptanoate (**8g**)




To a solution of **7k** (1.0 *eq.*) in MeOH was added NH_4F (30 *eq.*) at room temperature. Then the resultant mixture was stirred and heated to reflux for 2h. The solution was concentrated in vacuo and the residue was diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by saturated aqueous solution of NaHCO_3 , brine, dried over sodium sulfate (anhydrous) and concentrated in vacuo to give the corresponding primary alcohol **8e**, which was used immediately for next step directly.

To a solution of the above-obtained primary alcohol **8e** in toluene was added DPPA (2.0 *eq.*) and DBU (2.0 *eq.*). The reaction mixture was heated to reflux for 1h. After concentrated in vacuo, the residue was purified by silica gel column chromatography (EA/PE, 1:4) to afford the compound **8g** (82% over two steps) as an oil.

$[\alpha]_D^{25}$ -7.0 (c 0.87, EtOAc); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 4.94 (d, $J = 8.7$ Hz, 1H), 3.90 (d, $J = 5.1$ Hz, 1H), 3.67 (s, 3H), 3.33 - 3.18 (m, 2H), 2.51 (qd, $J = 15.6, 5.3$ Hz, 2H), 1.66 - 1.43 (m, 6H), 1.42 (s, 9H); $^{13}\text{C NMR}$ (151 MHz, CDCl_3) δ 172.03, 155.33, 79.30, 51.64, 51.22, 47.24, 39.03, 34.04, 28.48, 28.31, 23.30; HR-ESIMS m/z : calculated for $\text{C}_{13}\text{H}_{24}\text{N}_4\text{O}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 323.1690, found 323.1694.

Tert-butyl (S)-2-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate (**9b**)



To a solution of **7k** (1.0 *eq.*) in MeOH was added NH_4F (30 *eq.*) at room temperature. Then the resultant mixture was stirred and heated to reflux for 2h. The solution was concentrated in vacuo and the residue was diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by saturated aqueous solution of NaHCO_3 , brine, dried over sodium sulfate (anhydrous) and concentrated in vacuo to give the corresponding primary alcohol **8e**, which was used immediately for next step directly.



To a solution of the above-obtained primary alcohol **8e** in dry DCM was added Et_3N (3.0 *eq.*) and MsCl (2.0 *eq.*) at 0 °C. After 15 min, the resultant mixture was allowed to warm to room temperature and stirred for 2h at N_2 atmosphere. The reaction was then quenched with saturated aqueous NaHCO_3 solution and extracted with DCM for 3 times. The combined organic layer was washed successively with saturated aqueous KHSO_4 solution, saturated aqueous solution of NaHCO_3 , brine, and dried over anhydrous Na_2SO_4 , filtered, concentrated in vacuo to give the compound **8f** as an oil, which was pure enough and could be used for next step directly.

To a solution of the above-obtained compound **8f** in dry THF was added $t\text{-BuOK}$ (2.0 *eq.*) at 0 °C. After 20 min, the resultant mixture was allowed to warm to room temperature and stirred for 2h at N_2 atmosphere. The reaction was then quenched with saturated aqueous NH_4Cl solution. Volatiles of the reaction mixture were removed in vacuo. The solution was then diluted with water. The aqueous phase was extracted with ethyl acetate for 3 times. The combined organic phase was washed by brine, dried over sodium sulfate (anhydrous) and concentrated in vacuo. The residue was purified by silica gel column chromatography (EA/PE, 1:4) to afford the compound **9b** (75% over 3 steps) as an oil.



$[\alpha]_D^{25} +1.9$ (c 0.10, MeOH); $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 4.66 - 4.68 (m, 1H), 3.97 - 3.99 (m, 1H),

3.64 (s, 3H), 2.77 – 2.74 (m, 1H), 2.54 (ddd, $J = 45.2, 14.1, 7.6$ Hz, 2H), 1.66 – 1.56 (m, 4H), 1.53 – 1.46 (m, 2H), 1.43 (s, 9H); ^{13}C NMR (151 MHz, CDCl_3) δ 171.85, 154.68, 79.50, 51.63, 47.82, 39.06, 35.07, 28.35, 28.28, 25.24, 18.82; HR-ESIMS m/z : calculated for $\text{C}_{13}\text{H}_{23}\text{NO}_4\text{Na}^+$ $[\text{M}+\text{Na}]^+$: 280.1519, found 280.1523.


NMR Spectra of New Compounds and Selected Known Compounds




20240523-EY-LB-A02

Figure S3. $^1\text{H NMR}$ of **5a** (CDCl_3 , 600 MHz)Figure S4. $^{13}\text{C NMR}$ of **5a** (CDCl_3 , 150 MHz)


20240523-EY-LB-A03

Figure S5. ¹H NMR of **7a** (CDCl₃, 600 MHz)


20240523-EY-LB-A03

Figure S6. ¹³C NMR of **7a** (CDCl₃, 150 MHz)


20240516-EY-LB-B01

Figure S7. ¹H NMR of **3b** (CDCl₃, 600 MHz)


20240516-EY-LB-B01

Figure S8. ¹³C NMR of **3b** (CDCl₃, 150 MHz)


20240516-EY-LB-B02




20240516-EY-LB-B02





20240516-EY-LB-B03



20240516-EY-LB-B03








Figure S15. ^1H NMR of **5c** (CDCl_3 , 600 MHz)










Figure S16. ^{13}C NMR of **5c** (CDCl_3 , 150 MHz)







LYS-C03
AV-400-1H C03




Figure S23. ¹H NMR of **7d** (CDCl₃, 400 MHz)

LYS-C03-0611
AV-400-13C C03




Figure S24. ¹³C NMR of **7d** (CDCl₃, 100 MHz)




Figure S25. ^1H NMR of **3e** (CDCl_3 , 400 MHz)






Figure S26. ^{13}C NMR of **3e** (CDCl_3 , 100 MHz)






Figure S29. ¹H NMR of **7e** (CDCl₃, 400 MHz)




Figure S30. ¹³C NMR of **7e** (CDCl₃, 100 MHz)




Figure S31. ^1H NMR of **3f** (CDCl_3 , 400 MHz)






Figure S32. ^{13}C NMR of **3f** (CDCl_3 , 100 MHz)



LYS-F03-0621
AV-400-1H F03




Figure S35. ¹H NMR of **7f** (CDCl₃, 400 MHz)

LYS-F03
AV-400-13C F03






Figure S36. ¹³C NMR of **7f** (CDCl₃, 100 MHz)



20240716-EY-LB-T02




Figure S39. ^1H NMR of **5g** (CDCl_3 , 600 MHz)

20240716-EY-LB-T02




Figure S40. ^{13}C NMR of **5g** (CDCl_3 , 150 MHz)

20240717-EY-LB-T03




Figure S41. ¹H NMR of **7g** (CDCl₃, 600 MHz)








Figure S42. ¹³C NMR of **7g** (CDCl₃, 150 MHz)

20240905-EY-LB-X01




20240905-EY-LB-X01







20240910-EY-LB-X3




20240910-EY-LB-X03



20240812-EY-LB-E01



20240812-EY-LB-E01



20240812-EY-LB-E02




Figure S51. ¹H NMR of **5i (CDCl₃, 600 MHz)**

20240812-EY-LB-E02






Figure S52. ¹³C NMR of **5i (CDCl₃, 150 MHz)**

20240812-EY-LB-E03

Figure S53. ¹H NMR of 7i (CDCl₃, 600 MHz)

20240812-EY-LB-E03

Figure S54. ¹³C NMR of 7i (CDCl₃, 150 MHz)




Figure S55. ^1H NMR of **3j** (CDCl_3 , 600 MHz)






Figure S56. ^{13}C NMR of **3j** (CDCl_3 , 150 MHz)






Figure S59. ^1H NMR of **7j** (CDCl_3 , 600 MHz)






Figure S60. ^{13}C NMR of **7j** (CDCl_3 , 150 MHz)

20240821-EY-LB-N04

Figure S61. ¹H NMR of **8b** (CDCl₃, 600 MHz)

20240821-EY-LB-N04

Figure S62. ¹³C NMR of **8b** (CDCl₃, 150 MHz)




Figure S63. ¹H NMR of **8c** (CDCl₃, 600 MHz)








Figure S64. ¹³C NMR of **8c** (CDCl₃, 150 MHz)




20240830-EY-102

Figure S67. ^1H NMR of **3k** (CDCl_3 , 600 MHz)


20240830-EY-102



Figure S68. ^{13}C NMR of **3k** (CDCl_3 , 150 MHz)

20240902-EY-LB-V04



20240902-EY-LB-V04





PI-2409013




Figure S75. ^1H NMR of **9b** (CDCl_3 , 600 MHz)

PI-2409013




Figure S76. ^{13}C NMR of **9b** (CDCl_3 , 150 MHz)